| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Tsung-Tsair Yang, Su-Jane Wan. Aripiprazole and its human metabolite OPC14857 reduce, through a presynaptic mechanism, glutamate release in rat prefrontal cortex: possible relevance to neuroprotective interventions in schizophrenia. Synapse (New York, N.Y.). vol 62. issue 11. 2009-04-21. PMID:18720421. |
aripiprazole and its human metabolite opc14857 reduce, through a presynaptic mechanism, glutamate release in rat prefrontal cortex: possible relevance to neuroprotective interventions in schizophrenia. |
2009-04-21 |
2023-08-12 |
human |
| Matthew J Byerly, Ronald N Marcus, Quynh-Van Tran, James M Eudicone, Richard Whitehead, Ross A Bake. Effects of aripiprazole on prolactin levels in subjects with schizophrenia during cross-titration with risperidone or olanzapine: analysis of a randomized, open-label study. Schizophrenia research. vol 107. issue 2-3. 2009-04-20. PMID:19038534. |
effects of aripiprazole on prolactin levels in subjects with schizophrenia during cross-titration with risperidone or olanzapine: analysis of a randomized, open-label study. |
2009-04-20 |
2023-08-12 |
human |
| Matthew J Byerly, Ronald N Marcus, Quynh-Van Tran, James M Eudicone, Richard Whitehead, Ross A Bake. Effects of aripiprazole on prolactin levels in subjects with schizophrenia during cross-titration with risperidone or olanzapine: analysis of a randomized, open-label study. Schizophrenia research. vol 107. issue 2-3. 2009-04-20. PMID:19038534. |
this post-hoc sub-analysis of an 8-week, open-label study in outpatients with schizophrenia (cn138-215) examined short-term effects on prolactin levels during a switch from risperidone or olanzapine to aripiprazole 30 mg/day. |
2009-04-20 |
2023-08-12 |
human |
| Jonathan M Meyer, Lisa C Rosenblatt, Edward Kim, Ross A Baker, Richard Whitehea. The moderating impact of ethnicity on metabolic outcomes during treatment with olanzapine and aripiprazole in patients with schizophrenia. The Journal of clinical psychiatry. vol 70. issue 3. 2009-04-13. PMID:19192469. |
the moderating impact of ethnicity on metabolic outcomes during treatment with olanzapine and aripiprazole in patients with schizophrenia. |
2009-04-13 |
2023-08-12 |
Not clear |
| Irismar Reis de Oliveira, Hélio Elkis, Wagner Farid Gattaz, Ana Cristina Chaves, Eduardo Pondé de Sena, Fabio Gomes de Matos E Souza, João Alberto Campos, João Romildo Bueno, Jorge Alberto Costa E Silva, Mário Rodrigues Louzã, Paulo Belmonte de Abre. Aripiprazole for patients with schizophrenia and schizoaffective disorder: an open-label, randomized, study versus haloperidol. CNS spectrums. vol 14. issue 2. 2009-04-01. PMID:19238124. |
aripiprazole for patients with schizophrenia and schizoaffective disorder: an open-label, randomized, study versus haloperidol. |
2009-04-01 |
2023-08-12 |
Not clear |
| Natalie C Edwards, Jacqueline Pesa, Dennis M Meletiche, Luella Engelhart, Ann K Thompson, Jay Sherr, Riad Diran. One-year clinical and economic consequences of oral atypical antipsychotics in the treatment of schizophrenia. Current medical research and opinion. vol 24. issue 12. 2009-03-18. PMID:18954497. |
to assess the clinical and economic consequences of oral atypical antipsychotic treatment (aripiprazole, olanzapine, paliperidone er, quetiapine, risperidone, and ziprasidone) in schizophrenia over one-year from a us healthcare system perspective. |
2009-03-18 |
2023-08-12 |
Not clear |
| Ira D Glick, Michael Poyurovsky, Oxana Ivanova, Lorrin M Kora. Aripiprazole in schizophrenia patients with comorbid obsessive-compulsive symptoms: an open-label study of 15 patients. The Journal of clinical psychiatry. vol 69. issue 12. 2009-03-06. PMID:19026264. |
aripiprazole in schizophrenia patients with comorbid obsessive-compulsive symptoms: an open-label study of 15 patients. |
2009-03-06 |
2023-08-12 |
Not clear |
| Ira D Glick, Michael Poyurovsky, Oxana Ivanova, Lorrin M Kora. Aripiprazole in schizophrenia patients with comorbid obsessive-compulsive symptoms: an open-label study of 15 patients. The Journal of clinical psychiatry. vol 69. issue 12. 2009-03-06. PMID:19026264. |
this study examined aripiprazole treatment of patients with comorbid schizophrenia and obsessive-compulsive symptoms (ocs) that did not meet full criteria for ocd. |
2009-03-06 |
2023-08-12 |
Not clear |
| Ronette L Kolotkin, Patricia K Corey-Lisle, Ross D Crosby, Hong J Kan, Robert D McQuad. Changes in weight and weight-related quality of life in a multicentre, randomized trial of aripiprazole versus standard of care. European psychiatry : the journal of the Association of European Psychiatrists. vol 23. issue 8. 2009-03-05. PMID:18374544. |
we examined changes in weight and weight-related quality of life among community patients with schizophrenia treated with aripiprazole (ari) versus standard of care (soc), consisting of other marketed atypical antipsychotics (olanzapine, quetiapine, and risperidone). |
2009-03-05 |
2023-08-12 |
Not clear |
| Linda Hanssens, Gilbert L'Italien, Jean-Yves Loze, Ronald N Marcus, Miranda Pans, Wendy Kerselaer. The effect of antipsychotic medication on sexual function and serum prolactin levels in community-treated schizophrenic patients: results from the Schizophrenia Trial of Aripiprazole (STAR) study (NCT00237913). BMC psychiatry. vol 8. 2009-03-05. PMID:19102734. |
the effect of antipsychotic medication on sexual function and serum prolactin levels in community-treated schizophrenic patients: results from the schizophrenia trial of aripiprazole (star) study (nct00237913). |
2009-03-05 |
2023-08-12 |
Not clear |
| Linda Hanssens, Gilbert L'Italien, Jean-Yves Loze, Ronald N Marcus, Miranda Pans, Wendy Kerselaer. The effect of antipsychotic medication on sexual function and serum prolactin levels in community-treated schizophrenic patients: results from the Schizophrenia Trial of Aripiprazole (STAR) study (NCT00237913). BMC psychiatry. vol 8. 2009-03-05. PMID:19102734. |
the aim of this paper is to evaluate the effect of antipsychotics for the treatment of schizophrenia in a community based study on sexual function and prolactin levels comparing the use of aripiprazole and standard of care (soc), which was a limited choice of three widely used and available antipsychotics (olanzapine, quetiapine or risperidone) (the schizophrenia trial of aripiprazole [star] study [nct00237913]). |
2009-03-05 |
2023-08-12 |
Not clear |
| Philip G Janicak, Ira D Glick, Stephen R Marder, David T Crandall, Robert D McQuade, Ronald N Marcus, James M Eudicone, Sheila Assunção-Talbot. The acute efficacy of aripiprazole across the symptom spectrum of schizophrenia: a pooled post hoc analysis from 5 short-term studies. The Journal of clinical psychiatry. vol 70. issue 1. 2009-03-05. PMID:19192472. |
the acute efficacy of aripiprazole across the symptom spectrum of schizophrenia: a pooled post hoc analysis from 5 short-term studies. |
2009-03-05 |
2023-08-12 |
Not clear |
| Philip G Janicak, Ira D Glick, Stephen R Marder, David T Crandall, Robert D McQuade, Ronald N Marcus, James M Eudicone, Sheila Assunção-Talbot. The acute efficacy of aripiprazole across the symptom spectrum of schizophrenia: a pooled post hoc analysis from 5 short-term studies. The Journal of clinical psychiatry. vol 70. issue 1. 2009-03-05. PMID:19192472. |
to evaluate the efficacy of aripiprazole across a range of symptoms-positive, negative, disorganized thought, depression/anxiety, and hostility-in schizophrenia and schizoaffective disorder. |
2009-03-05 |
2023-08-12 |
Not clear |
| Lawrence S Kegeles, Mark Slifstein, W Gordon Frankle, Xiaoyan Xu, Elizabeth Hackett, Sung-A Bae, Robyn Gonzales, Jong-Hoon Kim, Beatriz Alvarez, Roberto Gil, Marc Laruelle, Anissa Abi-Dargha. Dose-occupancy study of striatal and extrastriatal dopamine D2 receptors by aripiprazole in schizophrenia with PET and [18F]fallypride. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 33. issue 13. 2009-02-19. PMID:18418366. |
dose-occupancy study of striatal and extrastriatal dopamine d2 receptors by aripiprazole in schizophrenia with pet and [18f]fallypride. |
2009-02-19 |
2023-08-12 |
Not clear |
| Lawrence S Kegeles, Mark Slifstein, W Gordon Frankle, Xiaoyan Xu, Elizabeth Hackett, Sung-A Bae, Robyn Gonzales, Jong-Hoon Kim, Beatriz Alvarez, Roberto Gil, Marc Laruelle, Anissa Abi-Dargha. Dose-occupancy study of striatal and extrastriatal dopamine D2 receptors by aripiprazole in schizophrenia with PET and [18F]fallypride. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 33. issue 13. 2009-02-19. PMID:18418366. |
these data show, for the first time, d(2) occupancy by aripiprazole in treated patients with schizophrenia in extrastriatal as well as striatal regions, with high occupancy for all doses. |
2009-02-19 |
2023-08-12 |
Not clear |
| Lawrence S Kegeles, Mark Slifstein, W Gordon Frankle, Xiaoyan Xu, Elizabeth Hackett, Sung-A Bae, Robyn Gonzales, Jong-Hoon Kim, Beatriz Alvarez, Roberto Gil, Marc Laruelle, Anissa Abi-Dargha. Dose-occupancy study of striatal and extrastriatal dopamine D2 receptors by aripiprazole in schizophrenia with PET and [18F]fallypride. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 33. issue 13. 2009-02-19. PMID:18418366. |
correlations of ratings of clinical improvement with regional occupancy suggest that aripiprazole, as do other antipsychotics, benefits positive symptoms of schizophrenia most directly through its modulation of striatal rather than cortical or other extrastriatal dopamine activity. |
2009-02-19 |
2023-08-12 |
Not clear |
| J Cordes, A Sinha-Röder, K G Kahl, J Malevani, J Thuenker, C Lange-Asschenfeldt, H Hauner, M W Agelink, A Klimk. [Therapeutic options for weight management in schizophrenic patients treated with atypical antipsychotics]. Fortschritte der Neurologie-Psychiatrie. vol 76. issue 12. 2009-02-09. PMID:18924059. |
extensive, selective literature review of 2500 articles from the last years (up to december 2007) predominantly from medline and cochrane, using as search terms "antipsychotic or schizophrenia or individual drug names (amisulpride, aripiprazole, clozapine, olanzapine, quetiapine, risperidone, ziprasidone)" and the terms "bmi, weight gain, metabolic syndrome, diabetes, lipid(s), cholesterol, triglycerides" was conducted. |
2009-02-09 |
2023-08-12 |
Not clear |
| Bruce J Kinon, Virginia L Stauffer, Sara Kollack-Walker, Lei Chen, Jennifer Sniadeck. Olanzapine versus aripiprazole for the treatment of agitation in acutely ill patients with schizophrenia. Journal of clinical psychopharmacology. vol 28. issue 6. 2009-02-02. PMID:19011427. |
olanzapine versus aripiprazole for the treatment of agitation in acutely ill patients with schizophrenia. |
2009-02-02 |
2023-08-12 |
Not clear |
| Bruce J Kinon, Virginia L Stauffer, Sara Kollack-Walker, Lei Chen, Jennifer Sniadeck. Olanzapine versus aripiprazole for the treatment of agitation in acutely ill patients with schizophrenia. Journal of clinical psychopharmacology. vol 28. issue 6. 2009-02-02. PMID:19011427. |
during the first 5 days of randomized treatment, olanzapine and aripiprazole displayed similar efficacy profiles for treating agitation associated with schizophrenia. |
2009-02-02 |
2023-08-12 |
Not clear |
| Vasilios G Masdrakis, Panagiotis Oulis, Iannis M Zervas, Nikolaos A Karakatsanis, Anastasios V Kouzoupis, Evangelos Karapoulios, Constantin R Soldato. The safety of the electroconvulsive therapy-aripiprazole combination: four case reports. The journal of ECT. vol 24. issue 3. 2009-01-22. PMID:18562946. |
we report the cases of 4 female inpatients--3 suffering from major depression and 1 from schizophrenia--who underwent ect--1 of them twice--while receiving aripiprazole (10-15 mg/d), as part of their regimen. |
2009-01-22 |
2023-08-12 |
Not clear |